Your browser doesn't support javascript.
Prevalence, clinical features, and outcomes of SARS-CoV-2 infection in pregnant women with or without mild/moderate symptoms: Results from universal screening in a tertiary care center in Mexico City, Mexico.
Cardona-Pérez, J Arturo; Villegas-Mota, Isabel; Helguera-Repetto, A Cecilia; Acevedo-Gallegos, Sandra; Rodríguez-Bosch, Mario; Aguinaga-Ríos, Mónica; Coronado-Zarco, Irma; León-Juárez, Moisés; Aguilar-Ayala, Diana; Valdespino-Vázquez, María Yolotzin; Moreno-Verduzco, Elsa Romelia; Rivera, María Antonieta; Valencia-Contreras, Carolina; Gómez-Sousa, María de Lourdes; Solis-Paredes, Mario; Frías-Madrid, Brenda; Velasco-Téllez, César; Rodriguez-Aldama, Juan Carlos; Avila-Sosa, Valeria; Galván-Contreras, Rafael; Figueroa-Damian, Ricardo; Cortés-Bonilla, Manuel; Estrada-Gutierrez, Guadalupe; Espino-Y-Sosa, Salvador; Irles, Claudine.
  • Cardona-Pérez JA; Dirección General, Instituto Nacional de Perinatología Isidro Espinosa de los Reyes, Mexico City, Mexico.
  • Villegas-Mota I; Unidad de Enfermedades Infecciosas y Epidemiología, Instituto Nacional de Perinatología Isidro Espinosa de los Reyes, Mexico City, Mexico.
  • Helguera-Repetto AC; Departamento de Immunobioquímica, Instituto Nacional de Perinatología Isidro Espinosa de los Reyes, Mexico City, Mexico.
  • Acevedo-Gallegos S; Departamento de Medicina Materno-Fetal, Instituto Nacional de Perinatología Isidro Espinosa de los Reyes, Mexico City, Mexico.
  • Rodríguez-Bosch M; Subdirección de Ginecología y Obstetricia, Instituto Nacional de Perinatología Isidro Espinosa de los Reyes, Mexico City, Mexico.
  • Aguinaga-Ríos M; Departamento de Genética y Genómica Humana, Instituto Nacional de Perinatología Isidro Espinosa de los Reyes, Mexico City, Mexico.
  • Coronado-Zarco I; Subdirección de Neonatología, Instituto Nacional de Perinatología Isidro Espinosa de los Reyes, Mexico City, Mexico.
  • León-Juárez M; Departamento de Immunobioquímica, Instituto Nacional de Perinatología Isidro Espinosa de los Reyes, Mexico City, Mexico.
  • Aguilar-Ayala D; Departamento de Immunobioquímica, Instituto Nacional de Perinatología Isidro Espinosa de los Reyes, Mexico City, Mexico.
  • Valdespino-Vázquez MY; Departamento de Anatomía Patológica, Instituto Nacional de Perinatología Isidro Espinosa de los Reyes, Mexico City, Mexico.
  • Moreno-Verduzco ER; Subdirección de Servicios auxiliares de Diagnóstico, Instituto Nacional de Perinatología Isidro Espinosa de los Reyes, Mexico City, Mexico.
  • Rivera MA; Unidad de Cuidados Intensivos del Recién Nacido, Instituto Nacional de Perinatología Isidro Espinosa de los Reyes, Mexico City, Mexico.
  • Valencia-Contreras C; Unidad de Cuidados Inmediatos al Recién Nacido, Instituto Nacional de Perinatología Isidro Espinosa de los Reyes, Mexico City, Mexico.
  • Gómez-Sousa ML; Departamento de Posgrado e Investigación, Instituto Nacional de Perinatología Isidro Espinosa de los Reyes, Mexico City, Mexico.
  • Solis-Paredes M; Departamento de Genética y Genómica Humana, Instituto Nacional de Perinatología Isidro Espinosa de los Reyes, Mexico City, Mexico.
  • Frías-Madrid B; Unidad de Cuidados Intensivos del Recién Nacido, Instituto Nacional de Perinatología Isidro Espinosa de los Reyes, Mexico City, Mexico.
  • Velasco-Téllez C; Departamento de Salud Mental, Instituto Nacional de Perinatología Isidro Espinosa de los Reyes, Mexico City, Mexico.
  • Rodriguez-Aldama JC; Unidad de Enfermedades Infecciosas y Epidemiología, Instituto Nacional de Perinatología Isidro Espinosa de los Reyes, Mexico City, Mexico.
  • Avila-Sosa V; Departamento de Fisiología y Desarrollo Celular, Instituto Nacional de Perinatología Isidro Espinosa de los Reyes, Mexico City, Mexico.
  • Galván-Contreras R; Unidad de Enfermedades Infecciosas y Epidemiología, Instituto Nacional de Perinatología Isidro Espinosa de los Reyes, Mexico City, Mexico.
  • Figueroa-Damian R; Departamento de Infectología e Inmunología, Instituto Nacional de Perinatología Isidro Espinosa de los Reyes, Mexico City, Mexico.
  • Cortés-Bonilla M; Dirección Médica, Instituto Nacional de Perinatología Isidro Espinosa de los Reyes, Mexico City, Mexico.
  • Estrada-Gutierrez G; Dirección de Investigación, Instituto Nacional de Perinatología Isidro Espinosa de los Reyes, Mexico City, Mexico.
  • Espino-Y-Sosa S; Subdirección de Investigación Clínica, Instituto Nacional de Perinatología Isidro Espinosa de los Reyes, Mexico City, Mexico.
  • Irles C; Departamento de Fisiología y Desarrollo Celular, Instituto Nacional de Perinatología Isidro Espinosa de los Reyes, Mexico City, Mexico.
PLoS One ; 16(4): e0249584, 2021.
Article in English | MEDLINE | ID: covidwho-1197373
ABSTRACT
The perinatal consequences of SARS-CoV-2 infection are still largely unknown. This study aimed to describe the features and outcomes of pregnant women with or without SARS-CoV-2 infection after the universal screening was established in a large tertiary care center admitting only obstetric related conditions without severe COVID-19 in Mexico City. This retrospective case-control study integrates data between April 22 and May 25, 2020, during active community transmission in Mexico, with one of the highest COVID-19 test positivity percentages worldwide. Only pregnant women and neonates with a SARS-CoV-2 result by quantitative RT-PCR were included in this study. Among 240 pregnant women, the prevalence of COVID-19 was 29% (95% CI, 24% to 35%); 86% of the patients were asymptomatic (95% CI, 76%-92%), nine women presented mild symptoms, and one patient moderate disease. No pregnancy baseline features or risk factors associated with severity of infection, including maternal age > 35 years, Body Mass Index >30 kg/m2, and pre-existing diseases, differed between positive and negative women. The median gestational age at admission for both groups was 38 weeks. All women were discharged at home without complications, and no maternal death was reported. The proportion of preeclampsia was higher in positive women than negative women (18%, 95% CI, 10%-29% vs. 9%, 95% CI, 5%-14%, P<0.05). No differences were found for other perinatal outcomes. SARS-CoV-2 test result was positive for nine infants of positive mothers detected within 24h of birth. An increased number of infected neonates were admitted to the NICU, compared to negative neonates (44% vs. 22%, P<0.05) and had a longer length of hospitalization (2 [2-18] days vs. 2 [2-3] days, P<0.001); these are potential proxies for illness severity. This report highlights the importance of COVID-19 detection at delivery in pregnant women living in high transmission areas.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pregnancy Complications, Infectious / COVID-19 Type of study: Diagnostic study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Long Covid Limits: Adult / Female / Humans / Infant, Newborn / Pregnancy / Young adult Country/Region as subject: Mexico Language: English Journal: PLoS One Journal subject: Science / Medicine Year: 2021 Document Type: Article Affiliation country: Journal.pone.0249584

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Pregnancy Complications, Infectious / COVID-19 Type of study: Diagnostic study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Long Covid Limits: Adult / Female / Humans / Infant, Newborn / Pregnancy / Young adult Country/Region as subject: Mexico Language: English Journal: PLoS One Journal subject: Science / Medicine Year: 2021 Document Type: Article Affiliation country: Journal.pone.0249584